Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AST-003
- Development stage
- Preclinical
- Lead developer
- Ascentawits Pharmaceuticals
- Modality
- Small Molecules
01
Overview
AST-003 is a small molecule targeted conjugate (SMDC) being developed by Ascentawits Pharmaceuticals for the treatment of esophageal cancer and gastric cancer. The drug is designed using the company's proprietary technology platform, which conjugates a small-molecule targeting fragment to a cytotoxic or chemotherapy payload. This approach aims to selectively deliver the therapeutic agent to tumor cells, potentially enhancing efficacy while minimizing systemic side effects compared to traditional chemotherapy. As of early 2024, AST-003 is in the preclinical registration study phase, moving toward Investigational New Drug (IND) filing.
02
Targets
AKR1C3 (Aldo-keto reductase family 1 member C3)DNA
Beyond the preview
Go deeper on AST-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AST-003.